Shire News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.03.18	Shire, NanoMedSyn In Research Deal To Treat Potential Lysosomal Storage Disorder (RTTNews)
23.03.18	Shire Plc: Court Prohibits Abhai From Marketing Generic Version Of ADDERALL XR (RTTNews)
12.03.18	Shire To Present Advancements In Chronic Hypoparathyroidism Research (RTTNews)
06.03.18	Caladrius Acquires Rights To Data Set, Filings For CD34+ Cell Therapy Program (RTTNews)
14.02.18	Shire Q4 Profit Surges On U.S. Tax Reform; Sees 2018 Profit Below View (RTTNews)
24.01.18	Shire: FDA Oks Technology Transfer Of CINRYZE Drug Product Manufacturing Process (RTTNews)
19.01.18	Shire Plc: Thomas Dittrich To Assume CFO Role On March 19 - Quick Facts (RTTNews)
16.01.18	The Race To Find A Treatment For NASH (RTTNews)
08.01.18	Shire To Operate As Two Divisions: Rare Disease And Neuroscience (RTTNews)
27.12.17	Shire Files For FDA Approval Of Plasma Manufacturing Facility In Covington (RTTNews)
13.12.17	Shire: ONCASPAR Formulation Receives Marketing Authorization In Europe (RTTNews)
05.12.17	Rani Therapeutics, Shire Partner To Develop Oral FVIII Delivery - Quick Facts (RTTNews)
30.11.17	Shire : FDA Grants Orphan Drug Designation For Anti-MAdCAM Antibody SHP647 (RTTNews)
20.11.17	Shire Remains Firmly In The Red After Early Decline (RTTNews)
13.11.17	Shire: CHMP Recommends Hemophilia A Drug ADYNOVI For EU Marketing Authorization (RTTNews)
27.10.17	Shire Q3 Adj. Profit Tops View, But Revenues Miss; Backs 2017 Outlook (RTTNews)
25.10.17	Shire Gets Orphan Drug Designation For Gene Therapy Candidate SHP654 (RTTNews)
13.09.17	Smart Medical Device Could Save Millions of Lives (PR Newswire)
12.09.17	Shire Plc Announces Fast Track Designation For SHP607 - Quick Facts (RTTNews)
11.09.17	Daily Technical Summary Reports on Healthcare Stocks -- Shire, Aerie Pharma, Heron Therapeutics, and United Therapeutics (PR Newswire)
15.08.17	Shire Announces Submission Of MAA For Lifitegrast - Quick Facts (RTTNews)
03.08.17	Shire Q2 Results Top Estimates; Explores Review Of Neuroscience Franchise (RTTNews)
26.07.17	Drug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics (PR Newswire)
06.07.17	Shire Submits Investigational NDA To FDA For Gene Therapy Candidate SHP654 (RTTNews)
22.06.17	Shire Says EMA Validates Veyvondi MAA For Treatment Of Von Willebrand Disease (RTTNews)
22.06.17	Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease (PR Newswire)
22.06.17	Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease (PR Newswire)
21.06.17	Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older (PR Newswire)
08.06.17	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Shire plc (SHPG) (PR Newswire)
07.06.17	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shire plc - SHPG (PR Newswire)
25.05.17	Shire to Participate at the Jefferies Healthcare Conference (PR Newswire)
25.05.17	Biotech Stocks Facing FDA Decision In June (RTTNews)
19.05.17	Shire To Highlight New Research On Chronic Hypoparathyroidism (RTTNews)
19.05.17	Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology (PR Newswire)
19.05.17	Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology (PR Newswire)
18.05.17	The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis (PR Newswire)
18.05.17	The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis (PR Newswire)
18.05.17	Shire: Lanadelumab Phase 3 Study Meets Endpoints - Quick Facts (RTTNews)
18.05.17	Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial (PR Newswire)
18.05.17	Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial (PR Newswire)
16.05.17	Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association (PR Newswire)
08.05.17	How These Healthcare Stocks are Faring? -- GlaxoSmithKline, Shire, Perrigo, and BioScrip (PR Newswire)
02.05.17	Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline (PR Newswire)
02.05.17	Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline (PR Newswire)
01.05.17	Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications (PR Newswire)
01.05.17	Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications (PR Newswire)
26.04.17	Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism (PR Newswire)
26.04.17	Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism (PR Newswire)
25.04.17	Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders (PR Newswire)
25.04.17	Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Shire plc (Spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten